- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Ezra Launches 3T MRI/CT Combination for Full-Body Scans
The Ezra Blueprint scan reportedly includes quantitative brain measurements, coronary calcium scoring (CAC) and a full-body MRI that provides screening for over 500 conditions.
Offering a combination of 3T magnetic resonance imaging (MRI) and computed tomography (CT) that can provide fatty liver assessment, lung cancer screening and aneurysm detection with two hour-long appointments, Ezra has launched the Ezra Blueprint scan.
The Ezra Blueprint scan reportedly includes neurodegenerative assessment with brain MRI, artificial intelligence (AI)-powered quantification of subcutaneous fat and MRI angiography for possible diagnosis of brain aneurysm and carotid artery disease, according to Ezra, the developer of the Ezra Blueprint.
The newly launched Ezra Blueprint scan reportedly combines 3T MRI and CT for full-body scanning that facilitates screening for over 500 conditions. (Images courtesy of Ezra.)
Other features included in the Ezra Blueprint are high-resolution imaging of knee and hip joints, CT-based coronary calcium scoring (CAC) and full-body MRI that enables screening of over 500 conditions, according to Ezra.
After two 60-minute appointments to complete Ezra Blueprint scanning, Ezra said patients will subsequently receive a detailed radiology report and a consultation review by medical providers associated with Ezra.
Seven Takeaways from New CT and MRI Guidelines for Ovarian Cancer Staging
January 20th 2025In an update of previous guidelines from the European Society of Urogenital Radiology published in 2010, a 21-expert panel offered consensus recommendations on the utility of CT, MRI and PET-CT in the staging and follow-up imaging for patients with ovarian cancer.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
